The Discounted Cash Flow (DCF) valuation of Royalty Pharma PLC (RPRX) is 45.53 USD. With the latest stock price at 35.64 USD, the upside of Royalty Pharma PLC based on DCF is 27.8%.
Based on the latest price of 35.64 USD and our DCF valuation, Royalty Pharma PLC (RPRX) is a buy. buying RPRX stocks now will result in a potential gain of 27.8%.
| Range | Selected | |
| WACC / Discount Rate | 5.5% - 7.5% | 6.5% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | 21.16 - 247.49 | 45.53 |
| Upside | -40.6% - 594.4% | 27.8% |